The pharmacologic management of Type 2 Diabetes has shifted from a glucose-centric model to a comprehensive, patient-centered approach focused on reducing cardiovascular and renal risk. Selecting the right therapy, as detailed in the Patient Care 5 curriculum, requires a pharmacist to consider patient comorbidities, medication costs, and potential side effects. This quiz will test your knowledge on the evidence-based guidelines and pharmacologic principles needed to navigate the complex landscape of Type 2 Diabetes treatment.
1. What is the universally recommended first-line pharmacologic agent for the management of Type 2 Diabetes, in conjunction with lifestyle modifications?
- a. Insulin
- b. A sulfonylurea
- c. Metformin
- d. An SGLT2 inhibitor
Answer: c. Metformin
2. A patient with Type 2 Diabetes has established atherosclerotic cardiovascular disease (ASCVD). After metformin, which drug class should be prioritized due to its proven cardiovascular benefit?
- a. A sulfonylurea
- a. A GLP-1 receptor agonist or an SGLT2 inhibitor with proven benefit
- c. A DPP-4 inhibitor
- d. Basal insulin
Answer: b. A GLP-1 receptor agonist or an SGLT2 inhibitor with proven benefit
3. What is the primary mechanism of action of SGLT2 inhibitors like empagliflozin?
- a. They increase insulin secretion from the pancreas.
- b. They increase insulin sensitivity in muscle and fat tissue.
- c. They inhibit glucose reabsorption in the proximal renal tubule.
- d. They inhibit the DPP-4 enzyme.
Answer: c. They inhibit glucose reabsorption in the proximal renal tubule.
4. A patient with Type 2 Diabetes and a history of heart failure with reduced ejection fraction (HFrEF) would derive the most benefit from adding which agent to their regimen?
- a. Pioglitazone
- b. An SGLT2 inhibitor
- c. Sitagliptin
- d. Glipizide
Answer: b. An SGLT2 inhibitor
5. Which class of oral antidiabetic agents carries the highest risk of causing hypoglycemia when used as monotherapy?
- a. Metformin
- b. Sulfonylureas
- c. DPP-4 inhibitors
- d. SGLT2 inhibitors
Answer: b. Sulfonylureas
6. The “Management of Type 2 Diabetes” is a specific lecture in which course?
- a. PHA5787C Patient Care 5
- b. PHA5104 Sterile Compounding
- c. PHA5703 Pharmacy Law and Ethics
- d. PHA5878C Patient Care 3
Answer: a. PHA5787C Patient Care 5
7. GLP-1 receptor agonists like liraglutide and semaglutide offer what additional benefit beyond glycemic control?
- a. Significant weight gain
- b. Weight loss
- c. Reduced risk of pancreatitis
- d. Low cost
Answer: b. Weight loss
8. Pioglitazone, a thiazolidinedione (TZD), is absolutely contraindicated in patients with:
- a. Hypertension
- b. Chronic kidney disease
- c. Symptomatic heart failure
- d. A history of smoking
Answer: c. Symptomatic heart failure
9. A common side effect of SGLT2 inhibitors that requires patient counseling is an increased risk of:
- a. Genital mycotic infections
- b. Lactic acidosis
- c. Pancreatitis
- d. Severe hypoglycemia
Answer: a. Genital mycotic infections
10. When should basal insulin be considered for a patient with Type 2 Diabetes?
- a. As first-line therapy for every patient.
- b. When A1c is >10% or there are signs of catabolism (e.g., weight loss).
- c. Only after all oral and other injectable options have been exhausted.
- d. Both b and c are appropriate times.
Answer: d. Both b and c are appropriate times.
11. The pharmacology of oral diabetes medications is a specific topic within the Patient Care 5 curriculum.
- a. True
- b. False
Answer: a. True
12. The primary mechanism of action of DPP-4 inhibitors like sitagliptin is:
- a. To increase urinary glucose excretion.
- b. To increase insulin sensitivity.
- c. To prevent the breakdown of endogenous incretin hormones.
- d. To stimulate insulin secretion directly.
Answer: c. To prevent the breakdown of endogenous incretin hormones.
13. A patient taking a sulfonylurea should be counseled on the importance of:
- a. Taking it on an empty stomach.
- b. Not skipping meals to avoid hypoglycemia.
- c. Monitoring for pancreatitis.
- d. Checking their blood pressure daily.
Answer: b. Not skipping meals to avoid hypoglycemia.
14. What is a key counseling point for a patient starting metformin?
- a. Take it on an empty stomach to increase absorption.
- b. Expect to gain weight.
- c. The risk of lactic acidosis is very high in all patients.
- d. GI side effects are common but can be minimized by slow titration and taking it with food.
Answer: d. GI side effects are common but can be minimized by slow titration and taking it with food.
15. A patient with Type 2 Diabetes and diabetic kidney disease with albuminuria should be on what class of medication for renal protection?
- a. A beta-blocker
- b. An ACE inhibitor or ARB
- c. A calcium channel blocker
- d. A loop diuretic
Answer: b. An ACE inhibitor or ARB
16. Which oral antidiabetic class is considered weight neutral?
- a. Sulfonylureas
- b. TZDs
- c. Insulin
- d. DPP-4 inhibitors
Answer: d. DPP-4 inhibitors
17. The management of diabetes complications is a topic within the Patient Care 5 curriculum.
- a. True
- b. False
Answer: a. True
18. Which sulfonylurea should be avoided in elderly patients and those with renal impairment due to its long-acting, active metabolite?
- a. Glipizide
- b. Glyburide
- c. Glimepiride
- d. All are equally safe.
Answer: b. Glyburide
19. What is a common side effect of TZDs like pioglitazone?
- a. Weight loss
- b. Peripheral edema
- c. Nausea
- d. Dehydration
Answer: b. Peripheral edema
20. An active learning session on diabetes is part of the Patient Care 5 course.
- a. True
- b. False
Answer: a. True
21. A patient is newly diagnosed with T2DM with an A1c of 7.2%. What is the most appropriate initial therapy?
- a. Insulin glargine
- b. Lifestyle modification plus metformin
- c. Liraglutide
- d. Sitagliptin plus glipizide
Answer: b. Lifestyle modification plus metformin
22. Which of the following is a cardiovascular benefit associated with some GLP-1 receptor agonists?
- a. Reduction in major adverse cardiovascular events (MACE).
- b. Worsening of heart failure.
- c. Increased risk of stroke.
- d. A significant increase in blood pressure.
Answer: a. Reduction in major adverse cardiovascular events (MACE).
23. The “pharmacology of injectable diabetes medications” is a lecture covered in the Patient Care 5 curriculum.
- a. True
- b. False
Answer: a. True
24. An active learning session on diabetes is part of which course?
- a. PHA5787C Patient Care 5
- b. PHA5163L Professional Skills Lab 3
- c. PHA5781 Patient Care I
- d. PHA5782C Patient Care 2
Answer: a. PHA5787C Patient Care 5
25. A patient taking an SGLT2 inhibitor should be counseled to hold the medication during periods of acute illness (“sick days”) to reduce the risk of:
- a. Euglycemic diabetic ketoacidosis.
- b. Severe hypoglycemia.
- c. Weight gain.
- d. Hypertension.
Answer: a. Euglycemic diabetic ketoacidosis.
26. The primary goal of combination therapy in T2DM is to:
- a. Use as many medications as possible.
- b. Target different pathophysiologic defects for a synergistic glucose-lowering effect.
- c. Increase the pill burden for the patient.
- d. Make the regimen more expensive.
Answer: b. Target different pathophysiologic defects for a synergistic glucose-lowering effect.
27. Which DPP-4 inhibitor does not require a dose adjustment for renal impairment?
- a. Sitagliptin
- b. Saxagliptin
- c. Linagliptin
- d. Alogliptin
Answer: c. Linagliptin
28. An active learning session on diabetes is part of which course module?
- a. Module 1: Diabetes Mellitus
- b. Module 3: Women’s Health
- c. Module 4: Medication Safety
- d. Module 8: Men’s Health
Answer: a. Module 1: Diabetes Mellitus
29. The choice of a second-line agent after metformin should be guided primarily by:
- a. The cost of the medication only.
- b. The presence of comorbidities like ASCVD, HF, or CKD.
- c. The pharmacist’s preference.
- d. The patient’s favorite color tablet.
Answer: b. The presence of comorbidities like ASCVD, HF, or CKD.
30. The “Management of Type 2 Diabetes” is a lecture within the Patient Care 5 curriculum.
- a. True
- b. False
Answer: a. True
31. When initiating basal insulin in a T2DM patient, a common starting dose is:
- a. 30 units at bedtime.
- b. 10 units at bedtime or 0.1-0.2 units/kg.
- c. 1 unit per kg of body weight.
- d. The same dose as their metformin.
Answer: b. 10 units at bedtime or 0.1-0.2 units/kg.
32. The primary side effect of alpha-glucosidase inhibitors like acarbose is:
- a. Hypoglycemia
- b. Flatulence and GI upset
- c. Weight gain
- d. Edema
Answer: b. Flatulence and GI upset
33. Which class of medications should be used with caution in patients with a personal or family history of medullary thyroid cancer?
- a. SGLT2 inhibitors
- b. DPP-4 inhibitors
- c. GLP-1 receptor agonists
- d. Sulfonylureas
Answer: c. GLP-1 receptor agonists
34. The pharmacist’s role in managing T2DM pharmacotherapy includes all of the following EXCEPT:
- a. Counseling on lifestyle modifications.
- b. Educating on medication administration and side effects.
- c. Writing the initial prescription for metformin.
- d. Assessing adherence to therapy.
Answer: c. Writing the initial prescription for metformin.
35. A patient on metformin is found to have a vitamin B12 deficiency. The appropriate management is:
- a. Stop the metformin immediately.
- b. Administer an oral vitamin B12 supplement.
- c. Start a sulfonylurea.
- d. No action is needed.
Answer: b. Administer an oral vitamin B12 supplement.
36. Which of the following is a primary benefit of metformin therapy?
- a. It causes significant weight loss.
- b. It has a high risk of hypoglycemia.
- c. It is generally weight-neutral and has a low risk of hypoglycemia.
- d. It is a new medication.
Answer: c. It is generally weight-neutral and has a low risk of hypoglycemia.
37. When adding an SGLT2 inhibitor to a patient’s regimen that includes a sulfonylurea, the pharmacist should be aware of an increased risk of:
- a. Hyperglycemia
- b. Hypoglycemia
- c. Lactic acidosis
- d. Pancreatitis
Answer: b. Hypoglycemia
38. The medicinal chemistry of diabetes medications is a topic within the Patient Care 5 curriculum.
- a. True
- b. False
Answer: a. True
39. A patient is newly diagnosed with T2DM and has an A1c of 11.5% with symptoms of hyperglycemia. What is an appropriate initial treatment regimen?
- a. Metformin alone
- b. Lifestyle modification alone
- c. Insulin therapy, with or without other agents.
- d. A DPP-4 inhibitor alone.
Answer: c. Insulin therapy, with or without other agents.
40. An active learning session covering diabetes pharmacotherapy is part of which course?
- a. PHA5787C Patient Care 5
- b. PHA5163L Professional Skills Lab 3
- c. PHA5781 Patient Care I
- d. PHA5782C Patient Care 2
Answer: a. PHA5787C Patient Care 5
41. The “-tide” suffix is characteristic of which drug class?
- a. DPP-4 inhibitors
- b. SGLT2 inhibitors
- c. GLP-1 receptor agonists
- d. TZDs
Answer: c. GLP-1 receptor agonists
42. Which class of medication works by improving insulin sensitivity in muscle and fat cells?
- a. Sulfonylureas
- b. Thiazolidinediones (TZDs)
- c. DPP-4 inhibitors
- d. SGLT2 inhibitors
Answer: b. Thiazolidinediones (TZDs)
43. A key aspect of modern T2DM management is:
- a. A glucose-centric approach only.
- b. A comprehensive cardiovascular risk reduction approach.
- c. Using as few medications as possible.
- d. Avoiding insulin at all costs.
Answer: b. A comprehensive cardiovascular risk reduction approach.
44. Which of the following is NOT a goal of T2DM pharmacotherapy?
- a. Achieve an individualized A1c target.
- b. Prevent long-term complications.
- c. Minimize side effects like hypoglycemia.
- d. Cure Type 2 Diabetes.
Answer: d. Cure Type 2 Diabetes.
45. A patient taking pioglitazone should be monitored for:
- a. Signs and symptoms of heart failure, such as edema and shortness of breath.
- b. Hypokalemia.
- c. Lactic acidosis.
- d. A severe rash.
Answer: a. Signs and symptoms of heart failure, such as edema and shortness of breath.
46. Educating a patient on how to monitor their blood glucose is a key skill for pharmacists.
- a. True
- b. False
Answer: a. True
47. A patient wants to avoid injections and has T2DM with established ASCVD. After metformin, which oral agent would be most appropriate?
- a. Glipizide
- b. Pioglitazone
- c. An SGLT2 inhibitor like empagliflozin.
- d. Sitagliptin
Answer: c. An SGLT2 inhibitor like empagliflozin.
48. An active learning session on diabetes is part of which course?
- a. PHA5787C Patient Care 5
- b. PHA5163L Professional Skills Lab 3
- c. PHA5781 Patient Care I
- d. PHA5782C Patient Care 2
Answer: a. PHA5787C Patient Care 5
49. The overall pharmacologic management of Type 2 Diabetes is:
- a. The same for every patient.
- b. A static plan that never changes.
- c. A dynamic, individualized process that is reassessed regularly.
- d. Focused only on post-prandial glucose.
Answer: c. A dynamic, individualized process that is reassessed regularly.
50. The ultimate goal of learning about the pharmacologic management of T2DM is to:
- a. Be able to recommend safe, effective, and evidence-based therapy tailored to each individual patient’s needs and comorbidities.
- b. Pass the endocrinology module exam.
- c. Memorize the brand and generic names of all diabetes drugs.
- d. Convince every patient to take an SGLT2 inhibitor.
Answer: a. Be able to recommend safe, effective, and evidence-based therapy tailored to each individual patient’s needs and comorbidities.
